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ABSTRACT
Glucocorticoids are among the most effective anti-inflammatory drugs, and are 
widely used for cancer therapy. Unfortunately, chronic treatment with glucocorticoids 
results in multiple side effects. Thus, there was an intensive search for selective 
glucocorticoid receptor (GR) activators (SEGRA), which retain therapeutic potential 
of glucocorticoids, but with fewer adverse effects. GR regulates gene expression by 
transactivation (TA), by binding as homodimer to gene promoters, or transrepression 
(TR), via diverse mechanisms including negative interaction between monomeric GR and 
other transcription factors. It is well accepted that metabolic and atrophogenic effects 
of glucocorticoids are mediated by GR TA. Here we summarized the results of extensive 
international collaboration that led to discovery and characterization of Compound A 
(CpdA), a unique SEGRA with a proven “dissociating” GR ligand profile, preventing GR 
dimerization and shifting GR activity towards TR both in vitro and in vivo. We outlined 
here the unusual story of compound’s discovery, and presented a comprehensive 
overview of CpdA ligand properties, its anti-inflammatory effects in numerous animal 
models of inflammation and autoimmune diseases, as well as its anti-cancer effects. 
Finally, we presented mechanistic analysis of CpdA and glucocorticoid effects in skin, 
muscle, bone, and regulation of glucose and fat metabolism to explain decreased CpdA 
side effects compared to glucocorticoids. Overall, the results obtained by our and other 
laboratories underline translational potential of CpdA and its derivatives for treatment 
of inflammation, autoimmune diseases and cancer.
INTRODUCTION
Synthetic glucocorticoids (Gcs) are the most 
frequently prescribed anti-inflammatory drugs, and 
have been used worldwide in the treatment of asthma, 
rheumatoid arthritis, inflammatory bowel disease, 
psoriasis, and other inflammatory and autoimmune 
diseases since early 1960s [1–3]. They are also extensively 
used as immunosupressants in the clinical management 
of organ transplantation, and as anti-cancer drugs, 
especially for the treatment of patients with hematological 
malignancies (leukemia, lymphoma, multiple myeloma).
Unfortunately chronic treatment with Gcs is 
associated with multiple adverse effects, including 
altered glucose metabolism, steroid-induced diabetes, 
osteoporosis, skin and muscle atrophy, alteration of 
behavior and mood. These clinical conditions motivated 
the active development of selective GR activators 
(SEGRA), novel glucocorticoid receptor (GR) ligands 
that preserve the therapeutic activity of Gcs, with fewer 
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adverse effects. Many candidate SEGRA molecules have 
been synthesized by industry and academia or identified by 
chemical library screening, with some, such as Mapracorat 
and PF-04171327, having reached clinical trials [4–10].
This review is focused on Compound A (CpdA), a 
non-steroidal SEGRA, which is a stable synthetic analogue 
of a natural compound found in Salsola tuberculatiformis 
Botschantzev (Fig. 1). We discuss the unusual history 
of CpdA discovery, its GR ligand properties, anti-
inflammatory and anti-cancer effects along with decreased 
metabolic and atrophogenic side effects, as compared to 
classical Gcs.
DISCOVERY OF COMPOUND A
Plants belonging to the genus Salsola (Family: 
Chenopodiaceae) are found in the arid and semi-arid 
regions of our planet with more than 60 different Salsola 
species found in Namibia and in the Republic of South 
Africa [11]. This genus is first mentioned in San folklore 
as traditional medicinal plants with Salsola aqueous 
extracts being used as oral contraceptives by San women 
[12]. During the investigation of the unusual biological 
effects of Salsola, it was confirmed that at least one 
member of this genus indeed contains active contraceptive 
compound(s). The chemical nature of these natural 
products has however, baffled scientists over many years.
In 1961 de Lange described a rare syndrome of 
prolonged gestation which sporadically occurred among 
Karakul sheep in the Keetmanshoop district in Namibia [13]. 
Salsola tuberculata, later renamed Salsola tuberculatiformis 
Botschantzev was subsequently identified to be responsible 
for this syndrome [14] [15]. This shrub is also known to 
local inhabitants as “gannabos”. In our investigations, 
using various derivatizing reagents to isolate the labile 
compounds in the form of their stabilized derivatives, 
we showed that treatment with trimethylammonium 
acetyl hydrazide chloride (Girard-T reagent), used for the 
isolation of aldehydes and ketones [16], removed all the 
contraceptive activity from active plant extracts [17]. The 
derivatives formed in this manner were isolated by solvent 
partitioning and then decomposed under acidic conditions 
to yield three compounds in pure form (Fig. 1A–1C). 
These compounds were identified by proton NMR and 
EI-mass spectrometry as 4-hydroxy-acetophenone (Fig. 1A), 
4-hydroxy-3-methoxy- acetophenone (Fig. 1B) and 
4-hydroxy-benzaldehyde (Fig. 1C) [17]. Although synthetic 
samples of both ketones did show some biological activity 
Figure 1: Chemical structures of selected phenolic compounds from S. tuberculatiformis, and their synthetic analog, 
Compound A. A–C. Chemical structures of selected bio-active phenolic compounds isolated from S. tuberculatiformis Botch extracts, 
D. an inactive compound, [2-(hydroxy)-2-(4-hydroxyphenyl)-ethyl]-methyl ammonium chloride (synephrine), and E. a synthetic analog 
2-(4-acetoxyphenyl)-2-chloro-N-ethyl ammonium chloride (Compound A). See also [111] for additional details.
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in rats, neither A or B, nor a mixture of A+B, could, at the 
levels found in the extract, account for the contraceptive 
activity of the plant. The aldehyde (Fig. 1C) was inactive. 
In later experiments without derivatizing reagents, we were 
able to isolate another pure compound which consistently 
appeared in active fractions. The compound was identified 
by NMR, UV and EI-mass spectrometry as 1-(4- hydroxy
phenyl)-2-methyl-aminoethanol or synephrine (Fig. 1D). 
This structure was subsequently confirmed by spectroscopic 
comparison with synthetic compounds as well as by the 
preparation of the same acylated derivatives from natural and 
synthetic material. Synthetic synephrine did not, however, 
show biological activity similar to that of the active plant 
extract.
These data suggested that compounds identified 
in active Salsola extracts probably arose as breakdown 
products from one or more, yet unknown, active 
precursor(s), pointing to the presence of phenolic 
compound(s) that contained a labile functional group. The 
labile group apparently decomposed under appropriate 
conditions to aldehydes, ketones or alcohols. Our results 
further suggested that the long duration of the biological 
tests for contraceptive activity was not compatible with 
the testing of the active compound(s), necessitating a more 
rapid and sensitive screening method for the evaluation of 
plant extracts or fractions. We developed a micro-assay 
based on the interference of the test compound with the 
substrate-induced difference spectrum of sheep adrenal 
cytochrome P450-dependent steroid 11β-hydroxylase 
(CYP11B1), the enzyme catalyzing the biosynthesis 
of cortisol and corticosterone from deoxycortisol and 
deoxycorticosterone, respectively [18–21]. We isolated 
a single compound to homogeneity using this assay and 
named it S2 [21]. Structure determination by NMR and 
mass spectrometry indicated the presence of an unstable 
aziridine, after which we subsequently synthesized a more 
stable aziridine precursor, Compound A (CpdA, Fig. 1E).
We showed that CpdA, similar to extracts prepared 
from dried plant material, caused contraception in rats 
[20] and interacted with two glucocorticoid-binding 
proteins: CYP11B1 and corticosteroid-binding globulin 
in plasma (CBG), while also being able to displace Gcs 
from CBG [22]. The fact that CpdA interacted with Gcs-
binding proteins, suggested that it could also bind to GR, 
a well known transcription factor (TF) that mediates the 
biological effects of glucocorticoid hormones [23–25].
COMPOUND A ACTS AS A SELECTIVE 
GR ACTIVATOR (SEGRA) AND AN 
ANTAGONIST OF THE ANDROGEN 
RECEPTOR
The GR belongs to a superfamily of nuclear 
hormone receptors and shares a characteristic three-
domain structure: a variable N-terminal region with 
transactivation domain responsible for gene activation, 
a conserved central DNA-binding domain with 
dimerization and nuclear localization sequences, and a 
conserved C-terminal ligand-binding domain [26–29].
In the absence of Gcs, the GR resides in 
cytoplasm bound to chaperones: heat shock proteins and 
immunophillins that control GR nuclear import [30, 31]. 
Upon Gcs binding, the GR translocates to the nucleus, 
where it regulates gene expression via (i) transactivation 
(TA), that requires GR-homodimer binding to 
palindromic glucocorticoid-responsive elements (GRE), 
and (ii) transrepression (TR), mediated via different 
mechanisms including negative interaction between GR 
and other TFs, such as NF-κB, AP-1, p53, STATs, IRF-3, 
CREB [12, 26–28, 32–34]. This interaction may occur 
in the nucleus or, as we have reported, in the cytoplasm 
[35], and does not require GR dimerization, as it could be 
mediated by the monomeric GR [26–28, 33, 36].
We and others reported that CpdA acts as a GR 
ligand. It binds to the GR with high affinity, with IC50 
in the nM range, as determined by competitive ligand–
binding assays in human and rodent cells expressing 
endogenous GR [35–37]. The effects of CpdA on major 
steps of GR activation: phosphorylation, dimerization, 
nuclear translocation and GR-DNA binding have been 
extensively studied. We showed, in fibroblasts, epithelial 
and lymphoid cells with endogenous or exogenous GR, 
that CpdA induced modest GR nuclear translocation [35, 
37, 39]. Using different approaches including fluorescence 
resonance energy transfer (FRET), we and others 
discovered that CpdA, unlike Gcs, did not elicit ligand-
induced GR dimerization [35–38]. Furthermore, CpdA did 
not induce GR phosphorylation at Ser211, critical for GR 
TA activity [37]. Consequently, CpdA did not significantly 
affect or even inhibited constitutive and Gcs-induced GR 
DNA binding and activation of endogenous genes and 
GRE.Luciferase reporters [35–37, 39]. In contrast, CpdA 
and classical Gcs have remarkably similar TR profiles, 
suppressing the activity of many pro-proliferative and 
anti-apoptotic TFs. Depending on cell context, CpdA has 
been shown to inhibit NF-κB, AP-1, Ets-1, Elk-1, SRF, 
NFATc [35, 37, 39]. Using cells with GR knockdown 
or lacking GR, we proved that CpdA inhibitory effects 
on TFs are GR-dependent [35, 37, 39]. Interestingly, 
in contrast to Gcs that usually do not interfere with TF 
nuclear translocation, CpdA significantly decreased/
delayed nuclear import of NF-κB and AP-1 proteins 
[35, 40].
The global effect of CpdA and the glucocorticoids 
on gene expression was compared by DNA array analyses 
in A549 lung carcinoma and Granta-519 lymphoma cells 
with endogenous GR; and in prostate cancer LNCaP-GR 
cells stably expressing exogenous GR. In both, epithelial 
and lymphoid cells, molecular TA signatures of CpdA and 
the synthetic glucocorticoid, dexamethasone (Dex), were 
different. In fact, CpdA was able to activate only 7–11% of 
the genes induced by Dex in LNCaP-GR and Granta-519 
cells (Fig. 2). However, their effects on the GR TR branch 
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were much more similar − CpdA was able to inhibit 
the expression of 31% and 66% of genes negatively 
regulated by Dex in lymphoma and prostate cancer cells, 
respectively (Fig. 2), and suppressed 32% of the genes 
negatively regulated by Dex in A549 lung cells [41]. In 
summary, our validated microarray results (Supplementary 
Fig. 1, Supplementary Tables S1 and S2; NCBI arrays with 
access numbers GSE71102 (LNCaP-GR) and GSE71099 
(Granta-519) confirmed at global level the unique CpdA 
capability to dissociate GR TA and TR functions, and to 
shift GR function towards TR.
In addition to its function as a SEGRA, CpdA acts 
as an antagonist of the androgen receptor (AR). Even 
though CpdA has a lower affinity for the AR compared to 
active androgens, CpdA induced considerable AR nuclear 
translocation [35, 42]. We and others showed that CpdA 
repressed the interaction between the NH(2)- and COOH-
terminal domains of the AR critical for its function, and 
inhibited both constitutive and dihydrotestosterone (DHT)-
induced AR-DNA binding and AR transcription activity in 
Luciferase reporter assays [35, 42]. These results suggest 
that the interaction of CpdA with the AR closely resembles 
the effects of well characterized anti-androgens, such as 
Casodex. CpdA did not significantly affect the activity of 
other steroid hormone receptors such as mineralcorticoid, 
progesterone, and estrogen receptors [36, 37].
It is important to note that CpdA is also 
characterized by its own molecular signature component, 
and regulated a subset of genes that were not affected by 
Gcs ([41], GEO submissions GSE71102  and GSE71099). 
Whether these genes were regulated via GR/AR remains 
to be investigated. Nevertheless, the therapeutic activity 
of CpdA was mostly mediated via GR or AR steroid 
receptors as discussed below.
THE BIOLOGICAL  ACTIVITY OF CPDA- 
POTENTIAL CLINICAL BENEFITS
Our findings have contributed to the understanding 
of the significance of GR TR mechanisms in the anti-
inflammatory and anti-cancer effects of Gcs [43–46]. In 
contrast, GR TA is proposed to underlie many adverse 
metabolic effects of Gcs [46–50]. Even though some genes 
activated by Gcs (such as DUSP1/MKP1, GILZ, IκBa) 
are involved in anti-inflammatory responses, while other 
genes inhibited by Gcs/GR (adrenocorticotropic hormone 
(ACTH) or collagens) are involved in steroidal side effects, 
it is now well established in the field that GR ligands, 
Figure 2: Global CpdA effect on the expression of glucocorticoid-responsive genes in epithelial and lymphoid 
cells. A. LNCaP-GR cells were treated with vehicle (EtOH), glucocorticoid Dexamethasone (Dex, 1 uM) or CpdA (5 uM) for 8 h; 
B. Granta-519 cells expressing endogenous GR, were treated with vehicle, Dex (1 uM) or CpdA (1 uM) for 16 h. Total RNA was extracted, 
and global gene expression changes were evaluated by Illumina DNA arrays (three individual RNA samples/group). Expression changes 
with fold change > 1.5, and p-value < 0.05 were considered biologically and statistically significant. Effect of CpdA on Dex-regulated 
genes: down-regulation (black); up-regulation (grey), no change (white).
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which do not support GR dimerization and predominantly 
activate the TR branch of GR signaling, should have a 
better therapeutic index than classical Gcs [36, 50–52]. 
Indeed, it is believed that GR ligands that “dissociate” 
GR TR from GR TA will retain the therapeutic activity 
of classical steroids, but will have reduced adverse side 
effects regarding bone, glucose and lipid metabolism. 
Thus, based on its GR ligand profile, CpdA was expected 
to exert pronounced anti-inflammatory and anti-cancer 
effects, while inducing fewer adverse effects typical for 
the classical synthetic Gcs that often limit their therapeutic 
applications. As discussed below, we had also anticipated 
that, compared to Gcs, CpdA would be less likely to 
induce patient resistance to GR-targeted therapy [39, 106].
Anti-inflammatory effects of compound A
Gcs remain a gold standard as anti-inflammatory 
drugs. They are effective against a wide range of 
inflammatory and autoimmune diseases characterized by 
the different types of CD4+ T helper (Th) lymphocytes. 
Th1 cells producing interferon (IFN)-α, interleukin (IL)-2, 
transcription factor T-bet, and tumor necrosis factor (TNF), 
as well as Th17 cells producing IL-17, are all implicated 
in the pathogenesis of autoimmune disorders including 
multiple sclerosis, rheumatoid arthritis, diabetes mellitus 
type 1; inflammatory bowel disease (Crohn’s disease) and 
acute organ rejection [53–61]. Th2 cells that produce IL-4, 
IL-5, IL-6, IL-9, IL-10, and IL-13 are mostly responsible 
for atopic disorders (such as atopic dermatitis, rhinitis, 
asthma), and allergies [54–60]. It is well known that Gcs 
can block both Th1/Th17 and Th2 inflammatory responses 
as well as inflammatory factors, such as NF-κB, central for 
the production of cytokines and chemokines involved in 
the activation and differentiation of Th cells.
The therapeutic activity of CpdA was extensively 
tested in comparison  with Gcs by us and other research 
groups in various Th1/Th17 and Th2 in vivo models of 
inflammation (Table 1). In the Th1/Th17 models, which 
included zymozan paw inflammation, collagen-induced 
arthritis (CIA), experimental autoimmune neuritis (EAN) 
and encephalomyelitis (EAE), type 1 diabetes and acute 
colitis, CpdA inhibited the development of clinical 
symptoms and morphological manifestations of disease, 
such as paw swelling, inflammation in joints, colon, 
pancreas, central nerve system and peripheral nerves [37, 
38, 62–66]. CpdA also reduced neuronal damage and 
demyelination, as well as progression of neuropathic  pain 
[65]. Furthermore, in the predominantly Th2-driven mouse 
asthma model, CpdA reduced inflammation and airway 
hyper-responsiveness [66]. In all the aforementioned 
models, CpdA decreased both the severity of localized 
clinical symptoms and the systemic signs of inflammation. 
However, CpdA doses in most studies were ~10-fold 
higher compared to Gcs, possibly due to a lower GR 
affinity and the non-steroidal nature of the compound 
[26, 33, 37].
CpdA has also been shown to ameliorate muscle 
pathology in mdx mice, an animal model for Duchene 
muscular dystrophy associated with abnormal muscle 
inflammation and activation of NF-κB. CpdA treatment 
for a period of 2 months, normalized limb strength and 
function and attenuated cathepsin-B enzyme activity 
(a surrogate marker for inflammation) [67].
Mechanisms of the anti-inflammatory effects of CpdA
At molecular level, the anti-inflammatory effects 
of CpdA were mediated mostly through blockage of 
inflammatory TFs including NF-κB, T-bet, STAT6, the 
latter being central to the Th2-driven asthma model [61, 
66, 68], which resulted in strong inhibition of expression 
of numerous pro-inflammatory cytokines and chemokines 
characteristic for each specific model. For example, in 
the zymosan-induced paw inflammation model, the anti-
inflammatory effect of CpdA was associated with the 
down-regulation of TNF-α-induced- and NF-κB-dependent 
pro-inflammatory genes such as IL-6, E-selectine, IL-8 and 
others [37]. In the model of experimental colitis induced 
by trinitrobenzene sulfonic acid, CpdA reduced the 
production of colonic TNF-α, IL-1, and COX-2 at mRNA 
level [69].
In models of autoimmune diseases such as arthritis, 
experimental autoimmune encephalomyelitis (EAE), 
autoimmune neuritis (EAN), and asthma, CpdA inhibited 
the expression of both Th1/Th17 and Th2 cytokines [38, 
62–66, 70–72]. In mice with EAE, for instance, CpdA was 
able to penetrate the blood-brain barrier and attenuated 
EAE symptoms via the inhibition of NF-κB nuclear 
translocation and the expression of NF-κB-driven pro-
inflammatory cytokines (INF-γ; IL-1β; TNF-α; IL-23; 
IL-17 and others) in the central nerve system [63]. In 
the Th2 asthma model, CpdA’s effects were mediated by 
the inhibition of TNF-α and Th2 inflammatory cytokines 
(IL-4, IL-5, IL-6) as well as blockage of NF-κB activity in 
lung [66]. In the model of Duchene muscular dystrophy, 
CpdA reduced expression of IL-6, CCL2, IFNγ, TNF-α, and 
IL-12p70 cytokines in muscle [67]. Interestingly, in 
models of inflammatory type 1 diabetes and autoimmune 
neuritis, CpdA, in addition to its inhibitory effect on 
Th1/Th17 cytokines, was able to switch Th1/Th17 
differentiation towards anti-inflammatory T regulatory 
(Treg) cell differentiation, an important mechanism for 
the resolving of inflammation [65, 73].
The molecular mechanisms of CpdA effects on 
NF-κB activation and the expression of inflammatory 
cytokines have been further corroborated in vitro, in 
cell lines and in primary cell cultures including mouse 
microglia and astrocytes, as well as synoviocytes from 
patients with rheumatoid arthritis [63, 70]. In most 
experiments, cells were activated by TNF-α or LPS to 
induce cytokine expression. Alternatively, HepG2 human 
liver cells were infected with Dengue virus to induce 
inflammatory cytokines and to model the “cytokine storm” 
that underlies the pathogenesis of Dengue hemorrhagic 
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Table 1: Anti-inflammatory effects of CpdA
Model description Therapeutic effects of CpdA Possible molecular mechanisms References
In vivo models of inflammation
Zymozan-induced 
inflamed paw
Decreased swelling Decreased NF-κB activity and inhibited 
expression of pro-inflammatory cytokines: IL-8, 
IL-6, and E-selectin
[37]
Collagen-induced 
arthritis
Decreased severity of disease;
Strong anti-inflammatory 
response
Inhibited TNF-α-induced production of pro-
inflammatory cytokines: IL-1β, IL-6 
[70], [38] 
[62]
Experimental 
autoimmune 
encephalomyelitis
Ameliorated clinical symptoms 
and disease severity; Reduced 
leukocyte infiltration in the spinal 
cord; Reduced neuronal damage 
and demyelination
Impaired NF-κB activation; 
Inhibited pro-inflammatory cytokines: INF-α,  IL-
1β, TNF-α,  IL-23, IL-17 
[63]; [64]
Experimental 
autoimmune neuritis
Inhibited paraparesis; Decreased 
infiltration of sciatic nerves with 
lymphocytes and macrophages 
and the progression of 
neuropathic pain; Decreased 
demyelination;
Modulated immune response: 
switch from Th1/Th17 towards 
anti-inflammatory T regulatory 
(Foxp3+/CD4+ Treg) response
Inhibited Th1/Th17 cytokines in microglia: IL1β, 
IL-17, IL-12p35, IFN-γ, TNF-α, and iNOS;
Increased Th2 cytokine and Foxp3 expression. 
[65]
Acute trinitrobenzene 
sulfonic acid-induced 
colitis
Ameliorated acute colitis;
Inhibited inflammatory cell 
infiltration into colon wall
Inhibited expression of pro-inflammatory genes: 
TNF-α, IL-1β, and COX-2 
[69]
Streptozotocin model 
of type 1 diabetes 
Protected against development of 
diabetes;
Modulated peripheral immune 
response (switch from Th1/Th17 
towards anti-inflammatory T 
regulatory/ Treg response)
Inhibited pro-inflammatory cytokines: IL-1β, 
TNF-α, IL-6; 
Up-regulated expression of anti-inflammatory 
cytokines: IL-4 and IL-10 
[73]
Ovalbumin-induced 
Th2-driven asthma 
model
Reduced inflammatory cell 
infiltration in lungs, cytokine 
production, mucus and Ig 
production;
Reduced development of airway 
hyperresponsiveness (AHR)
Inhibited NF-κB activity and nuclear 
translocation;
Inhibited STAT6 activity and nuclear 
translocation;
Inhibited expression of Th2 cytokines: IL-4, IL-5, 
and IL-13
[66]
mdx (Dystrophin-
deficient) mice, an 
animal model for 
Duchene muscular 
dystrophy
Reduced muscle inflammation;
Improved strength and function 
of the limbs
Inhibited NF-κB signaling in muscle; Inhibited 
expression of IL-6, CCL2, IFN-γ, TNF-α, IL- 
12p70 
[67]
In vitro models of inflammation
Synovial fibroblasts 
from patients with 
rheumatoid arthritis
Inhibited NF-κB activity and IKK 
phosphorylation;
Induced IκB-α accumulation; Inhibited IL-1β 
expression
[106];
[38]
[70]
(Continued )
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fever [74]. The aforementioned experiments demonstrated 
that CpdA inhibited NF-κB and the expression of pro-
inflammatory cytokines in a GR-dependent fashion, and 
confirmed that CpdA acts as “dissociated” GR ligand, as 
it was incapable of activating GR target genes, such as 
DUSP1/MKP1, GILZ, FKBP51 [38, 62, 65, 69, 70]. 
Interestingly, in vitro experiments confirmed that CpdA, 
in contrast to Gcs, can do both: inhibit expression of 
inflammatory cytokines and induce the expression of anti-
inflammatory cytokines such as IL-10 [65].
Anti-cancer effects of Compound A as a mono-
therapy and in combination with proteasome 
inhibitors
Gcs usually promote cell differentiation and inhibit 
proliferation, and have proven anti-cancer activity 
[44, 45, 75, 76]. Synthetic Gcs have been extensively 
used clinically against leukemia, lymphomas, and 
multiple myeloma. The steroids are typically paired 
with traditional chemotherapies (cyclophosphamide, 
doxorubicin, vincristine, methotrexate), and newer 
(proteasome inhibitors) agents [77–80]. Gcs are also used 
in combination therapy of patients with epithelial cancers, 
mostly for palliative treatment of metastasis-related pain, 
decreasing nausea and other side effects of chemotherapy 
[81]. However, in some cases they have been used as anti-
cancer drugs, and even as a mono-therapy, as in the case 
of elderly patients with prostate cancer [82].
In contrast to anti-inflammatory effects, the anti-
cancer effects of CpdA were uncovered more recently. Our 
findings showed that CpdA inhibited growth and viability 
of numerous cancer cells including prostate cancer, 
lymphoma, leukemia and multiple myeloma as well as 
melanoma cell lines (Table 2). The anti-cancer effect of 
CpdA was GR-dependent, and in cancer cells with GR 
knockdown, CpdA was significantly less toxic (Table 2) 
[35, 39, 83]. In prostate cancer cell models, the cytotoxic 
concentrations of CpdA were in the range of 10−5 to 10−6 M, 
in standard growth and apoptosis tests inmonolayer 
cultures as well as in colony-forming assays (Fig. 3A 
and [35, 83]). Moreover, using prostate cancer cells with 
different AR and GR status, we demonstrated clearly that 
CpdA could exert its cytostatic effect via both receptors 
which correlated with CpdA’s dual GR/AR ligand 
properties shown in our earlier studies [35].
The leukemia and lymphoma cells appeared to be far 
more sensitive to CpdA than epithelial cancer cells. CpdA 
was equally or more potent than Gcs in the inhibition of 
growth and survival of transformed lymphoid cell lines, as 
well as in primary cell cultures from acute T cell leukemia 
patients [39].
We subsequently used human cancer cells 
xenografts to assess the anti-cancer activity of CpdA 
in vivo (Figs. 3B and 3C), and demonstrated that CpdA 
inhibited growth of PC3 prostate cancer  cell xenografts 
by 40% and Granta-519 mantle cell lymphoma xenografts 
by 70% when used at doses ~ 8–10 μg/animal, which were 
lower than the anti-inflammatory doses of CpdA [37, 63].
As mentioned above, Gcs are mostly used in 
combination anti-cancer therapies, frequently with 
proteasome inhibitors such as Bortezomib (BZ) - a 
proteasome inhibitor approved by FDA in 2003 for the 
treatment of hematological malignancies [84, 85]. While 
the biological effects of GR ligands depend on GR levels, 
proteasome inhibitors are known to stabilize the GR and to 
Model description Therapeutic effects of CpdA Possible molecular mechanisms References
Co-cultivation of 
BMSC (bone marrow 
stem cells) with 
osteoclasts
Inhibited IL-1β, TNF-α, IL-6
expression
[105]
Dengue virus 
(DENV) infection of 
HepG2 transformed 
hepatocyte cells
Reduced DENV production Reduced the expression of DENV-induced 
cytokines: CXCL10 and TNF-α; 
Decreased leukocyte migration
[74]
Murine 
T-lymphocytes
Inhibited T-bet (T box expressed in T-cells) 
factor central for Th1 response; Decreased GR-
dependent transrepression 
[61]
Primary microglial 
cells
Inhibited NF-κB activation; Inhibited TNF-α and 
IL-1β cytokines
[63]
Immortalized murine 
macrophage cell line 
RAW 264.7
Attenuated expression of TNF-α, iNOS, and IL-1, 
but increased expression of anti-inflammatory 
IL-10;
Induced macrophage differentiation towards M2 
anti-inflammatory phenotype 
[65]
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prevent Gcs-induced GR degradation [86, 87]. We showed 
that BZ indeed induced GR accumulation in lymphoma, 
leukemia and prostate cancer cells, and enhanced CpdA’s 
profile as a dissociated GR ligand further shifting GR 
signaling to TR [35, 39, 83]. Moreover, we showed that BZ 
sensitized lymphoma and prostate cancer cells to CpdA, 
and we revealed a pronounced GR-dependent cooperative 
CpdA and BZ anti-cancer effect [35, 39, 83]. Similar results 
were obtained in multiple myeloma cells MM.1S expressing 
endogenous functional GR, in which the anti-cancer effects 
of CpdA and BZ were also synergistic [39].
The mechanisms of anti-cancer effect of CpdA
There is growing evidence that, in parallel with 
inhibition of growth and survival, Gcs launch an anti-
apoptotic program and, under certain conditions, can 
even protect cancer cells from chemotherapy-induced 
apoptosis [81, 88–91]. We and others have reported that 
Figure 3: Anti-cancer effect of CpdA in colony forming assay and in xenograft models. A. Inhibitory effect of CpdA on 
anchorage-independent cell growth. LNCaP-GR and LNCaP-V (empty virus) -infected cells on 1% soft agar were treated with vehicle 
or 5 uM CpdA as described ([35], Supplementary Table S3). B, C. Effect of CpdA on prostate cancer cells (PC3) and lymphoma cells 
(Granta-519) xenograft growth in vivo. Granta-519 cells (B, 10 million cells/site in BD Matrigel Matrix) and PC3 cells (C, 1.2 million cells/
site) were injected s.c. into athymic nu/nu female mice. Mice with established tumors (>50 mm3) were treated by i.p. injections 3 times/wk 
for 35 days with: CpdA (solid line), Dex (dotted line) or vehicle (0.1% Etoh in saline, dashed line).
Table 2: Cytotoxic effect of CpdA in cancer cells in vitro
Cell line Origin Effect CpdA concentration References
RWPE-1 Non-transformed prostate cells +/− 10 uM [35]
LNCaP-GR Prostate Cancer (PC) ++ 10 uM [35, 83]
PC3 PC +++ 10 uM [35]
DU145 PC +++ 10 uM [35]
Hematopoietic SCs − 10 uM - 50 uM Budunova et al., unpublished
Granta-519 Mantle cell lymphoma (MCL) ++ 1 uM [39]
NCEB-1 MCL +++ 1 uM [39]
MM-1.S Multiple myeloma +++ 1 uM [39]
CEM T cell leukemia ++ 3 uM [39]
A375 Melanoma ++ 10 uM Yemelyanov and Budunova, unpublished
C8161 Melanoma ++ 10 uM Yemelyanov and Budunova, unpublished
Cancer cells and non-transformed cells of the same origin were treated with CpdA or vehicle, and the cytotoxic effect was 
evaluated by cell counting as described [35, 39, 83]. The cytotoxic effect is depicted + (25%)/ ++ (30–50%)/ +++ (>50%) 
cell number reduction in CpdA versus vehicle control group.
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Gcs can activate inhibitors of apoptosis IAPs, MAP kinase 
phosphatase DUSP1/MKP1 (resulting in AP1 inhibition), 
pro-survival serum and glucocorticoid-inducible protein 
kinase SGK1, as well as increasing the expression of anti-
apoptotic genes from the Bcl-2 family (Bcl-2 and Bcl-xl) 
[83, 88–90, 92]. In addition, we showed that Gcs prevent 
BZ-induced endoplasmic reticulum (ER) stress in prostate 
cancer cells [83].
CpdA on the other hand, in contrast to Gcs did not 
induce an anti-apoptotic self-defense program in cancer 
cells. Moreover, CpdA enhanced lethal BZ-induced ER 
stress [83]. Our findings highlighted the potential benefits 
of combining a SEGRA such as CpdA with proteasome 
inhibitors to trigger the maximal potential of anti-cancer 
GR signaling.
Cell desensitization to activated GR signaling: 
CpdA versus glucocorticoids
Chronic treatment with Gcs frequently result in the 
development of resistance to steroids (tachyphylaxis) [93], 
which is in part mediated by the decreased GR levels in the 
cells. It is known that GR agonists induce the repression 
of GR transcription as well as the destabilization of the 
GR at mRNA and protein levels [94]. The inhibition of 
GR transcription by Gcs is mediated by the recruitment 
of activated GR to the negative GRE in exon 6 of GR, 
followed by the assembly of a GR-NCoR1-HDAC3 
repression complex at the transcriptional start site of the GR 
gene [94]. Interestingly, CpdA did not induce GR loading 
in exon 6 (Haegeman and Cidlowski, unpublished data).
Although Gcs also induce GR degradation by 
proteasome [87], CpdA, in contrast, did not trigger 
significant GR degradation in lymphoid cells or in 
synoviocytes [38, 39, 70]. The differential effects of CpdA 
on crucial steps in GR degradation by the proteasome, 
such as GR phosphorylation and ubiquitination for 
example, remain to be investigated.
Another mechanism of cell desensitization common 
to Gcs is mediated by a negative feedback loop via the GR 
molecular chaperone FKBP51, also referred to as FK506-
binding protein 5 [95]. FKBP51 sequesters the GR in the 
cytoplasm and prevents nuclear translocation [96, 97]. 
We showed that, in contrast to Gcs, CpdA did not activate 
FKBP51 gene expression [39, 83].
In summary, our experiments demonstrated that 
CpdA failed to induce major mechanisms underlying the 
development of cell resistance to activated GR signaling.
Adverse metabolic and atrophogenic effects: 
CpdA versus glucocorticoids
Together with their excellent therapeutic effects, 
Gcs are notorious for their multiple adverse side effects 
which develop in different organs and tissues during 
chronic treatment. The long list of undesirable effects 
includes changes in glucose and fat metabolism, Cushing’s 
syndrome, diabetes, glaucoma, osteoporosis, muscle and 
skin atrophy, decreased wound healing, changes in mood 
and central nervous system functions, growth retardation 
in pediatric patients, and infertility. Many of these 
effects are severe and sometimes irreversible [98–100]. 
A considerable number of metabolic and atrophogenic 
effects of Gcs are due to their catabolic activity in 
peripheral organs/tissues, in which protein degradation 
and lipolysis are induced to stimulate glucocneogenesis 
in liver and to maintain high blood glucose levels 
[12, 46]. These effects involve activation of genes 
encoding gluconeogenetic enzymes, such as glucose-
6-phosphatase, phosphoenolpyruvate carboxykinase 
(PEPCK), tyrosine aminotransferase as well as fatty acid 
synthase [12, 46, 64], linking many adverse Gcs effects to 
GR TA. In addition, we and others found that the induction 
of GR target gene REDD1 (regulated in development and 
DNA damage response 1) is central to the atrophogenic 
effects of Gcs in skin, subcutaneous adipose and muscle 
[101, 102]. Importantly, REDD1 KO animals appeared to 
be protected against Gcs-induced skin atrophy and muscle 
waste [101, 103].
Although CpdA side effects during chronic in vivo 
treatment remain to be comprehensively analyzed, our 
results and reports by others, indicate that CpdA induces 
fewer adverse effects both in control animals and in animal 
models of diabetes, rheumatoid arthritis, osteoporosis, 
and Duchene muscle dystrophy when compared to Gcs 
[67, 73, 104, 105]. Indeed, in contrast to Gcs, CpdA did 
not induce key liver gluconeogenic enzymes, glucose-6-
phosphatase and PEPCK, did not affect hepatic glycogen 
formation and, as a result did not induce hyperglycemia 
and hyperinsulinemia after systemic chronic animal 
treatment [64, 106]. It is important to note that although 
decreased β-cell insulin production and insulin resistance 
induced by Gcs may lead to the induction of type II 
diabetes or aggravation of pre-existing diabetes in patients 
[47], CpdA did not impair glucose metabolism, suggesting 
a reduced risk for induced type II diabetes by this GR 
ligand. Furthermore, CpdA was effective in the prevention 
and treatment of experimental inflammatory diabetes, 
which resembles type I diabetes in patients [73].
In contrast to steroids, CpdA did not induce muscle 
waste when it was used systemically in mdx mice [67]. 
CpdA also did not induce skin atrophy in rats and mice 
when applied topically [107, 108], which we have 
correlated with its inability to induce atrophogene REDD1 
in skin (Budunova, Haegeman, unpublished). In addition, 
the inhibitory effect of CpdA on collagen type I and III 
gene expression in skin, the key molecular change related 
to atrophy in dermis, was favorably diminished when 
compared to Gcs [107, 108].
Chronic administration of Gcs also leads to bone 
loss and osteoporosis due to reduced bone turnover, 
induction of osteoblast and osteocyte apoptosis, negative 
effects on Collagen 1 and Runx2, genes directly involved 
in bone formation, as well as activation of osteoclasts via 
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activation of RANKL and osteopontin genes [12, 67]. The 
negative effects of CpdA on the bone metabolism were 
significantly weaker compared to Gcs in both newborn and 
adult mice [67, 104, 105].
Exogenous Gcs suppress the hypothalamic 
pituitary adrenal (HPA) axis, a major component of the 
neuroendocrine system, which controls stress adaptation 
and many body functions, including the immune response, 
mood and emotions, energy storage, while also regulating 
the biosynthesis of corticosteroids via ACTH in the 
adrenals [12]. ACTH is the key regulatory hormone in 
the HPA feedback loop, and its expression is negatively 
regulated by Gcs [12]. It is interestingly to note that even 
though GR TR by CpdA is overall very efficient, CpdA 
did not affect the HPA axis significantly as was assessed 
by the lack of changes in corticosterone and ACTH serum 
levels [63, 64].
It is however, important to state that CpdA has some 
limitations possibly due to its restricted chemical stability. 
CpdA has a relatively narrow therapeutic window and 
when used at high doses (~15 mg/kg) for longer periods 
it may gradually induce apoptosis via GR-independent 
metabolites [8, 64]. Although the anti-cancer effect of 
CpdA in the lymphoma xenograft model was achieved 
at lower doses (Fig. 3C), without inducing significant 
adverse effects during 4–6 wk animal treatment, the 
treatment of inflammatory diseases in animal models are 
reported to require higher doses of CpdA [62, 63, 65, 66].
Thus, in our ongoing work we have initiated 
synthesis of more stable SEGRA using CpdA as a 
prototype. To date, we and others have used a racemic 
Compound A for all in vitro and in vivo studies, even 
though it is known that enantiomers of chiral molecules 
including steroid receptor ligands often exhibit different 
chemical and biological properties [109, 110]. Thus, 
alternative approaches to improve CpdA ligand binding 
and pharmacological properties could involve its synthesis 
as an enantiopure compound.
CONCLUSIONS
In this review, we summarized the results of 
10 years of research collaboration between several 
academic organizations: Stellenbosch University 
(S. Africa), University of Ghent (Belgium), Northwestern 
University (Chicago, USA) and the Blokhin Cancer Center 
(Moscow, Russia), that led not only to the identification of 
CpdA as a unique SEGRA but also to the characterization 
of its ligand properties as well as its anti-inflammatory 
and anti-cancer activities. These studies unraveled the 
unusual biological properties of CpdA, but also provided 
a greater understanding of the mechanisms underlying the 
therapeutic and adverse effects of Gcs. To date no other 
SEGRA has been shown to exhibit the distinct profile of 
a dissociating GR ligand as has CpdA both in vitro and 
in vivo − preventing GR dimerization and subsequent 
TA, while switching GR activity towards TR. We also 
showed that CpdA is a dual GR/AR ligand and can act as 
an anti-inflammatory anti-androgen. The very beneficial 
pharmacological profile of CpdA can be attributed to its 
properties as a GR ligand retaining the therapeutic anti-
inflammatory and anti-cancer potential of Gcs, while 
inducing fewer side effects. CpdA is furthermore less 
likely to induce patient resistance as it does not activate the 
major mechanisms of cell desensitization typical for Gcs. 
Overall, these properties make CpdA and its prospective 
derivatives very attractive candidates for clinical 
applications in the treatment of various inflammatory and 
autoimmune diseases such as rheumatoid arthritis, asthma 
and type I diabetes, neuropathy, muscle dystrophies as 
well as cancer, especially in combinational chemotherapy.
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